Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026

Synopsis

- 42 risk management plans (RMPs) for centrally authorised medicines: 10 RMPs reviewed for new medicines, 32 RMPs reviewed for authorised medicines More information can be found under 'Post-authorisation safety studies'.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.